New startup ideas · Health and bio · Healthcare and bio
startup idea
Datavena
The marketplace where your biology earns royalties from drug developers.
Datavena is a consumer app where people connect wearables, genomes and health records and license access to pharma and AI labs - and get paid recurring royalties every time their data trains a model.
- Marketplace
- Consumer
- $100B+ market
- Creates a new category
- Global from day one
3/5
venture judge
14
similar startups, last 2 years (125 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,100 · 5 weeks · 15 prospects
For $1,100 and 5 weeks, prove AI-biotech buyers will pay a $3,000 deposit at marketplace rates for a consented diabetes cohort while consumers sign up to supply it for under $3 each.
Riskiest assumption · Data leads at AI-biotech and pharma companies will pay marketplace rates - a real premium over their existing CRO and hospital-broker contracts - for consented, metered, audit-ready wearable and phenotype data from a named disease cohort.
1Focus group: who and where
Head of data science or translational lead at a Series A-B AI drug discovery startup (10-60 people, the Atlas Discovery profile) currently assembling human phenotype training data ad hoc from CROs and hospital record brokers ahead of a model milestone this quarter.
where to find 15 · The Bits in Bio Slack community, where techbio data leads answer DMs; the YC Startup Directory filtered to recent biotech and AI drug discovery batches, including Atlas Discovery named on the card, plus a Crunchbase list of Series A AI drug discovery companies; the published HLTH 2026 speaker and exhibitor list as a cold outreach list; warm introductions through Nucleate's chapter network as the fourth path.
2Sell first, build later
A 90-day design-partner pilot sold before the enclave exists: metered training access to a 500-member consented type 2 diabetes cohort (wearable and CGM streams, self-reported labs, full consent audit trail), cohort live within 90 days of pilot start, with the buyer shaping the metering and audit format.
the ask · $15,000 per pilot, $3,000 deposit up front; indicated production pricing of $2,000-5,000 per metered training run thereafter
a real yes · A real yes is a signed pilot order with the $3,000 deposit paid; a signed LOI with a dated start is a weak yes to log separately; data 'partnership' talk, unpaid evaluation requests and scientist enthusiasm count for nothing.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Buyer rate and provenance calls
$150 · 12 days
List 15 data and translational leads via Bits in Bio, the YC directory and the HLTH list, and run 20-minute calls asking three things: what they pay brokers and CROs per cohort today, where that data fails them (consent provenance, wearable depth, longitudinal coverage), and what a metered, audit-ready 500-member type 2 diabetes cohort would be worth. One founder runs all calls and logs every dollar figure quoted.
keep going if · 6 of 15 buyers say current sources fail on consent provenance or wearable depth AND name a budget of $10,000 or more for a pilot cohort
2. Paid pilot close
$250 · 14 days
Send a two-page pilot order to every buyer who named a budget: $15,000 for 90 days of metered training access to the 500-member consented cohort, $3,000 deposit up front, buyer shapes the metering and consent-audit format. Follow up twice; log stated objections, especially 'brokers are cheaper', verbatim.
keep going if · 2 of 15 buyers sign the pilot order and pay the $3,000 deposit
3. Supply cost smoke test
$700 · 10 days
Run a consumer landing page - 'get paid royalties when your CGM and wearable data trains medicine, $120 first-year guarantee' - and recruit type 2 diabetics through r/diabetes_t2, the TuDiabetes forum, T2D Facebook groups and $500 of Meta and Reddit ads. Measure signup cost and how many complete a detailed consent-preview step; collect no actual health data.
keep going if · 200 email signups at under $3 each, with 30% completing the consent-preview step
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$3,000
per prospect, refundable
how · A paid design-partner pilot invoiced up front: a $3,000 deposit against the $15,000 pilot fee, signed by the buyer's data or BD lead as a simple services order - startups this size can pay without full procurement, and only paid money at marketplace rates refutes the objection that brokers already sell adjacent data cheaply. set up: Stripe Invoicing ↗
what it reserves · One of two design-partner slots, first access to the 500-member type 2 diabetes cohort, and direct input on the metering, royalty and consent-audit format.
refund · Refunded in full if the consented cohort is not live within 90 days of the agreed pilot start date.
target · 2 paid $3,000 deposits from 15 buyer conversations within 35 days
before taking money · Collect no genomes, records or wearable data during the test - sell scoped pilot orders and deposits only - until privacy counsel clears the consent flow under HIPAA, state genetic privacy laws and the Washington My Health My Data Act.
Go: build it if
2 paid $3,000 deposits from 15 buyers plus consumer signups under $3 each with 30% consent-preview completion - recruit the real 500-member cohort and build the minimum metering layer for one buyer, deferring the full enclave R&D.
Kill: stop if
0 deposits and fewer than 3 of 15 buyers naming a budget above broker prices, or consumer signup cost above $10 with under 10% consent completion - demand pays broker rates and supply is too expensive to aggregate.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
You're training human-response models on whatever cohort data brokers will license, with consent chains you can't always show an auditor. I'm building Datavena: a consented type 2 diabetes cohort - wearables, CGM, self-reported labs - where every training run is metered, members earn royalties, and provenance is contractual. I'm scoping two paid 90-day pilots: access to the first 500-member cohort for $15,000. Worth 20 minutes for you to tell me whether this data would clear your bar?
landing page
Consented human phenotype data your auditors will sign off on. $15,000 pilot: 90 days of metered training access to a 500-member consented type 2 diabetes cohort - reserve a slot with a $3,000 deposit. Book a pilot scoping call.
deposit terms
Your $3,000 deposit reserves one of two design-partner pilot slots and is credited against the $15,000 pilot fee. It is refunded in full if we do not deliver the 500-member consented cohort within 90 days of your agreed pilot start date. The balance is invoiced only when the cohort is live and your first training run is scheduled.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
63
Idea Score, 0-100 · raw 39.0 x 1.61
Crowded
competition: more crowded than 79% of ideas · headwind x0.60
+4.7
government priorities, secondary (151 matching grants)
Trend
70
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)85
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
43
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain0
100x potential
60
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis100
- Moat axis80
- Neighbours still alive31
- Technologist judge50
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were marketplace, biology, earns, royalties, drug, developers, consumer, connect.
The idea in full
- What
- Datavena is a consumer app where people connect wearables, genomes and health records and license access to pharma and AI labs - and get paid recurring royalties every time their data trains a model. The deep tech is a federated compute layer built over roughly three years of R&D: buyers' models train against member data inside secure enclaves, so raw data never leaves the member's custody and every training run is metered and billed. Consumers join self-serve; the supply side is the product, and the capital goes into ops - onboarding, verification, and device partnerships that preinstall Datavena at the point of sale.
- Why now
- The brief counts five recent companies pitching drug discovery and Atlas Discovery (YC S26) is funded to predict human response to drugs in clinical trials - the demand side for real human phenotype data is crowded and paying, while elegslab's NAMs platform shows regulators pushing toward alternatives to animal data; nobody in the brief is building the consented human supply side.
- Wedge: first customer and entry point
- Recruit 50,000 wearable owners in one disease community (type 2 diabetes) with a guaranteed first-year royalty, and sign two AI-biotech buyers for that single high-value cohort before generalizing.
- Path to 100x
- Global drug R&D spend exceeds $250B a year and is shifting toward models trained on human rather than animal data; a royalty marketplace creates a category - individuals as recurring data licensors - and the winner is whoever owns the consumer installed base, since buyers go where the members are. 100x is tens of millions of members, device-maker preinstall deals as the distribution lock, and a take rate on a multi-billion-dollar annual flow of training-access fees.
- Ceiling
- If synthetic and organoid-derived data (the NAMs wave) gets good enough, demand for consented human data flattens and Datavena caps out as a niche recruitment channel.
- Closest real companies, as the generator saw them
- Atlas Discovery, Omanta and RonanRx Inc. all consume human biological data to build models or products; Harbor runs trial operations. Datavena sits underneath all of them as the metered, consented data supply they currently assemble ad hoc.
- Main risk
- Pharma buyers refuse to pay marketplace rates while hospital record brokers and trial CROs sell adjacent data cheaply through existing contracts.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
$250B drug R&D flow is the right size, but consumer data-royalty supply aggregation needs three years of R&D before any buyer pays marketplace rates.
Bootstrapper
1/5
Three years of federated enclave R&D plus device preinstall deals before a single royalty is billed.
Operator
1/5
Three years of R&D to sell data pharma already sources cheaply through CRO and hospital broker contracts, with consumers as the unpaid supply side.
Technologist
3/5
Federated enclave metering is real three-year engineering, but the winner is decided by consumer installed base and device preinstall deals, not by the compute layer.
Risk
1/5
A royalty marketplace for genomes and health records under GDPR consent rules is the heaviest unlicensed regulatory exposure in this batch.
trends
2/5
Consented health-data marketplaces were pitchable in 2023; the NAMs demand story names no dated 2025-2026 regulation or platform move that opens a window.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (marketplace, biology, earns, royalties, drug, developers, consumer, connect): 125 all-time, 14 from the last two years. Same matching as Idea Check.
Realizse's mission is to accelerate the world's transition to sustainable products. Realizse is a Web3 platform for the circular economy. Realizse creates verifiable assets with digital twins supporting circularity, sustainability, and traceability for supply chain interoperability.
Genomic medicine for transplanted livers.
Developer of a goods comparison platform designed to find out discount deals and offers on consumer durables. The company's platform offers complete transparency by instantly showing shopping options across all retail marketplaces including new, used, refurbished, rental, unbranded and in-store, enabling consumers to compare prices, shop across marketplaces, and maximize savings by making better buying decisions.
Developer of a microstock marketplace designed to connect digital artists and filmmakers for the promotion of digital media. The company's marketplace offers a web-based platform to purchase worldwide stock animation, video footage, after effects templates, apple motion templates, and online music tracks, enabling users to view various forms of digital media and purchase according to their requirements.
Marketplace to get stuff from overseas
Digital Grid is a retail supply contract or a power supply contract with a service provider using the digital grid platform.
Leverages technology to revolutionize payments in emerging markets by making them safer, more convenient, and beneficial for consumers, merchants, and cities
Vira Regen develops noninvasive bioelectronic devices for gene-targeted tissue regeneration.
Reprogramming immunomodulation using AI to cure cancer
Full Stack Pharmaceutical Company for Personalized Peptides and GLP-1s
AI-native CRO for clinical trial operations
AI Infra for real-time vision applications
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1595
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
118
opportunities open now in the sector
- Development of a milk analyzing technology for the detection of antibiotic contamination using fluorescence spectroscopy and artificial intelligence.awardhigh relevance
NIH / FDA · SBIR phase I · $200K · posted 2026-09-30
- Economical, easy-to-use and highly sensitive illicit drugs detection in bodily fluids using surface-enhanced Raman scattering (SERS).awardhigh relevance
NIH / NIDA · SBIR phase I · $311K · posted 2026-07-01
- Modeling Receptor-ligand interactions for Drug Discoveryfrom Cryo-EM data using AIawardhigh relevance
NIH / NIGMS · SBIR phase I · $218K · posted 2025-09-01
- A Real-Time Mass Spectrometry Platform for In-Process Monitoring and Cell State Analysisawardhigh relevance
NIH / NIGMS · SBIR phase I · $303K · posted 2025-08-02
- Investigating Ultra-High-Quality Graphene-Based Cryo-EM Device Architecture for Higher Reproducibility, Speed, and Resolutionawardhigh relevance
NIH / NIGMS · SBIR phase I · $307K · posted 2025-08-01
NIH / NIAMS · SBIR phase I · $313K · posted 2025-08-01
- IND-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ringawardhigh relevance
NIH / NICHD · SBIR phase II · $1M · posted 2026-09-25
NIH / NIA · SBIR phase II · $1M · posted 2026-09-23
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Consumer
- Business model
- Marketplace
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- R&D first, revenue after 3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Self-serve
- Moat
- Distribution moat
- Geography
- Global from day one
- Regulation
- Some regulation
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.